A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge

Virology

Volumn 397, Issue 1, 2010, Pages 187-198

  Mandell, Robert B ^a   Koukuntla, Ramesh ^a   Mogler, Laura J K ^a   Carzoli, Andrea K ^a   Freiberg, Alexander N ^b   Holbrook, Michael R ^b   Martin, Brian K ^c   Staplin, William R ^a   Vahanian, Nicholas N ^a,c   Link, Charles J ^a,c   Flick, Ramon ^a  

^a BioProtection Systems Corporation   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c NEWLINK GENETICS   (United States)

Author keywords

Chimeric; Rift Valley fever virus; Vaccine; Virus like particle

Indexed keywords

CYTOKINE; GAG PROTEIN; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; RIFT VALLEY FEVER BUNYAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HEMORRHAGIC FEVER; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOPRECIPITATION; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTECTION; RAT; RIFT VALLEY FEVER BUNYAVIRUS; SPLEEN CELL; SUCROSE DENSITY GRADIENT CENTRIFUGATION; TRANSMISSION ELECTRON MICROSCOPY; VIRUS PARTICLE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOKINES; FEMALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; MOLONEY MURINE LEUKEMIA VIRUS; RATS; RATS, INBRED WF; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, VIROSOME; VIRAL PROTEINS; VIROSOMES; VIRUS REPLICATION;

MOLONEY MURINE LEUKEMIA VIRUS; MUS; RATTUS; RIFT VALLEY FEVER VIRUS;

EID: 73949093570     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.11.001     Document Type: Article

References (137)

1. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356 19 (2007) 1915-1927
2. Abdel-Motal U.M., Guay H.M., Wigglesworth K., Welsh R.M., and Galili U. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. J. Virol. 81 17 (2007) 9131-9141
3. Al-Hazmi M., Ayoola E.A., Abdurahman M., Banzal S., Ashraf J., El-Bushra A., Hazmi A., Abdullah M., Abbo H., Elamin A., Al-Sammani el T., Gadour M., Menon C., Hamza M., Rahim I., Hafez M., Jambavalikar M., Arishi H., and Aqeel A. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin. Infect. Dis. 36 3 (2003) 245-252
4. Anderson Jr. G.W., and Peters C.J. Viral determinants of virulence for Rift Valley fever (RVF) in rats. Microb. Pathog. 5 4 (1988) 241-250
5. Anderson Jr. G.W., Slone Jr. T.W., and Peters C.J. Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb. Pathog. 2 4 (1987) 283-293
6. Anderson Jr. G.W., Lee J.O., Anderson A.O., Powell N., Mangiafico J.A., and Meadors G. Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats. Vaccine 9 10 (1991) 710-714
7. Anderson Jr. G.W., Rosebrock J.A., Johnson A.J., Jennings G.B., and Peters C.J. Infection of inbred rat strains with Rift Valley fever virus: development of a congenic resistant strain and observations on age-dependence of resistance. Am. J. Trop. Med. Hyg. 44 5 (1991) 475-480
8. Andersson A.M., Melin L., Bean A., and Pettersson R.F. A retention signal necessary and sufficient for Golgi localization maps to the cytoplasmic tail of a Bunyaviridae (Uukuniemi virus) membrane glycoprotein. J. Virol. 71 6 (1997) 4717-4727
9. Andre F.E., and Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad. Med. J. 63 Suppl 2 (1987) 169-177
10. Anonymous. Outbreak of Rift Valley fever, Yemen, August-October 2000. Wkly. Epidemiol. Rec. 75 48 (2000) 392-395
11. Babcock G.J., Esshaki D.J., Thomas Jr. W.D., and Ambrosino D.M. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J. Virol. 78 9 (2004) 4552-4560
12. Balkhy H.H., and Memish Z.A. Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int. J. Antimicrob. Agents 21 2 (2003) 153-157
13. Barrett J.W., Sun Y., Nazarian S.H., Belsito T.A., Brunetti C.R., and McFadden G. Optimization of codon usage of poxvirus genes allows for improved transient expression in mammalian cells. Virus Genes 33 1 (2006) 15-26
14. Besselaar T.G., and Blackburn N.K. Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies. Arch. Virol. 121 1-4 (1991) 111-124
15. Billecocq A., Gauliard N., Le May N., Elliott R.M., Flick R., and Bouloy M. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 378 2 (2008) 377-384
16. Bird B.H., Albarino C.G., and Nichol S.T. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362 1 (2007) 10-15
17. Bird B.H., Albarino C.G., Hartman A.L., Erickson B.R., Ksiazek T.G., and Nichol S.T. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82 6 (2008) 2681-2691
18. Bos E.C., Luytjes W., and Spaan W.J. The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity. J. Virol. 71 12 (1997) 9427-9433
19. Bosio C.M., Moore B.D., Warfield K.L., Ruthel G., Mohamadzadeh M., Aman M.J., and Bavari S. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 326 2 (2004) 280-287
20. In: Burger W., and Burge M.J. (Eds). Digital Image Processing: An algorithmic introduction using Java (2008), Springer-Verlag, New York
21. Caplen H., Peters C.J., and Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66 Pt 10 (1985) 2271-2277
22. Capua I., Cattoli G., and Marangon S. DIVA-a vaccination strategy enabling the detection of field exposure to avian influenza. Dev. Biol. (Basel) 119 (2004) 229-233
23. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., and Hu Y.C. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26 15 (2008) 1855-1862
24. Ciarlet M., Crawford S.E., Barone C., Bertolotti-Ciarlet A., Ramig R.F., Estes M.K., and Conner M.E. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J. Virol. 72 11 (1998) 9233-9246
25. Collett M.S., Purchio A.F., Keegan K., Frazier S., Hays W., Anderson D.K., Parker M.D., Schmaljohn C., Schmidt J., and Dalrymple J.M. Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus. Virology 144 1 (1985) 228-245
26. Cox M.M., Patriarca P.A., and Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi. Viruses 2 6 (2008) 211-219
27. El-Attar L., Olivera S.L., Mackie A., Charpilienne A., Poncet D., Cohen J., and Bridger J.C. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine 27 (2009) 3201-3208
28. Elliott R.M. In: Elliott R.M. (Ed). The Bunyaviridae (1996), Plenum Press, New York and London
29. Elliott R.M., Schmaljohn C.S., and Collett M.S. Bunyaviridae genome structure and gene expression. Curr. Top. Microbiol. Immunol. 169 (1991) 91-141
30. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F., and Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173 5 (2004) 3148-3154
31. Filone C.M., Heise M., Doms R.W., and Bertolotti-Ciarlet A. Development and characterization of a Rift Valley fever virus cell-cell fusion assay using alphavirus replicon vectors. Virology 356 1-2 (2006) 155-164
32. Flick R., and Bouloy M. Rift Valley fever virus. Curr. Mol. Med. 5 8 (2005) 827-834
33. Frank-Peterside N. Response of laboratory staff to vaccination with an inactivated Rift Valley fever vaccine-TSI-GSD 200. Afr. J. Med. Med. Sci. 29 2 (2000) 89-92
34. Fromantin C., Jamot B., Cohen J., Piroth L., Pothier P., and Kohli E. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response. J. Virol. 75 22 (2001) 11010-11016
35. Garcea R.L., and Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr. Opin. Biotechnol. 15 6 (2004) 513-517
36. Geisbert T.W., and Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10 12 Suppl (2004) S110-S121
37. Gerdes G.H. Rift Valley fever. Rev. Sci. Tech. 23 2 (2004) 613-623
38. Gerrard S.R., and Nichol S.T. Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein. J. Virol. 76 23 (2002) 12200-12210
39. Gerrard S.R., and Nichol S.T. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 357 2 (2007) 124-133
40. Gheysen D., Jacobs E., de Foresta F., Thiriart C., Francotte M., Thines D., and De Wilde M. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59 1 (1989) 103-112
41. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., Fourneau M.A., Colau B., Suzich J., Losonksy G., Martin M.T., Dubin G., and Wettendorff M.A. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 33-34 (2006) 5937-5949
42. Goldmann C., Petry H., Frye S., Ast O., Ebitsch S., Jentsch K.D., Kaup F.J., Weber F., Trebst C., Nisslein T., Hunsmann G., Weber T., and Luke W. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J. Virol. 73 5 (1999) 4465-4469
43. Gori Savellini G., Di Genova G., Terrosi C., Di Bonito P., Giorgi C., Valentini M., Docquier J.D., and Cusi M.G. Immunization with Toscana virus N-Gc proteins protects mice against virus challenge. Virology 375 2 (2008) 521-528
44. Green T.D., Newton B.R., Rota P.A., Xu Y., Robinson H.L., and Ross T.M. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20 1-2 (2001) 242-248
45. Grgacic E., and Anderson D. Virus-like particles; passport to immune recognition. Methods 40 60-65 (2006)
46. Grgacic E.V., and Anderson D.A. Virus-like particles: passport to immune recognition. Methods 40 1 (2006) 60-65
47. Guo L., Lu X., Kang S.M., Chen C., Compans R.W., and Yao Q. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology 313 2 (2003) 502-513
48. Haas J., Park E.C., and Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6 3 (1996) 315-324
49. Habjan M., Penski N., Wagner V., Spiegel M., Overby A.K., Kochs G., Huiskonen J.T., and Weber F. Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology 385 2 (2009) 400-408
50. Haferkamp S., Fernando L., Schwarz T.F., Feldmann H., and Flick R. Intracellular localization of Crimean-Congo Hemorrhagic Fever (CCHF) virus glycoproteins. Virol. J. 2 (2005) 42
51. Haffar O., Garrigues J., Travis B., Moran P., Zarling J., and Hu S.L. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64 6 (1990) 2653-2659
52. Hammonds J., Chen X., Ding L., Fouts T., De Vico A., zur Megede J., Barnett S., and Spearman P. Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. Virology 314 2 (2003) 636-649
53. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-Martins C.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., and Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
54. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., Mast T.C., Robinson R., Murphy B.R., Karron R.A., Dillner J., Schiller J.T., and Lowy D.R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93 4 (2001) 284-292
55. Haynes J.R., Cao S.X., Rovinski B., Sia C., James O., Dekaban G.A., and Klein M.H. Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res. Hum. Retrovir. 7 1 (1991) 17-27
56. Haynes J.R., Dokken L., Wiley J.A., Cawthon A.G., Bigger J., Harmsen A.G., and Richardson C. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27 4 (2009) 530-541
57. Hunter P., Erasmus B.J., and Vorster J.H. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort. J. Vet. Res. 69 1 (2002) 95-98
58. Jiang B., Estes M.K., Barone C., Barniak V., O'Neal C.M., Ottaiano A., Madore H.P., and Conner M.E. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 17 7-8 (1999) 1005-1013
59. Johnson J.E., and Chiu W. Structures of virus and virus-like particles. Curr. Opin. Struct. Biol. 10 2 (2000) 229-235
60. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., Garland S.M., Harper D.M., Tang G.W., Ferris D.G., Steben M., Jones R.W., Bryan J., Taddeo F.J., Bautista O.M., Esser M.T., Sings H.L., Nelson M., Boslego J.W., Sattler C., Barr E., and Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 9574 (2007) 1693-1702
61. Kan V.L., Manischewitz J., King L.R., and Golding H. Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection. AIDS 21 4 (2007) 521-524
62. Kark J.D., Aynor Y., and Peters C.J. A Rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am. J. Epidemiol. 116 5 (1982) 808-820
63. Kark J.D., Aynor Y., and Peters C.J. A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection. Vaccine 3 2 (1985) 117-122
64. Khanam S., Khanna N., and Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24 42-43 (2006) 6513-6525
65. Kobasa D., Rodgers M.E., Wells K., and Kawaoka Y. Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks. J. Virol. 71 9 (1997) 6706-6713
66. Kozak M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res. 12 2 (1984) 857-872
67. Kozak M. Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo. Nature 308 5956 (1984) 241-246
68. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15 20 (1987) 8125-8148
69. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene 299 1-2 (2002) 1-34
70. LaBeaud A.D., Muchiri E.M., Ndzovu M., Mwanje M.T., Muiruri S., Peters C.J., and King C.H. Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya. Emerg. Infect. Dis. 14 8 (2008) 1240-1246
71. Lagerqvist N., Naslund J., Lundkvist A., Bouloy M., Ahlm C., and Bucht G. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol. J. 6 (2009) 6
72. Li P.P., Naknanishi A., Tran M.A., Ishizu K., Kawano M., Phillips M., Handa H., Liddington R.C., and Kasamatsu H. Importance of Vp1 calcium-binding residues in assembly, cell entry, and nuclear entry of simian virus 40. J. Virol. 77 13 (2003) 7527-7538
73. Li Z., Yi Y., Yin X., Zhang Z., and Liu J. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. PLoS ONE 3 5 (2008) e2273
74. Licata J.M., Johnson R.F., Han Z., and Harty R.N. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 78 14 (2004) 7344-7351
75. Liu L., Celma C.C., and Roy P. Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol. J. 5 (2008) 82
76. Lokugamage K.G., Yoshikawa-Iwata N., Ito N., Watts D.M., Wyde P.R., Wang N., Newman P., Kent Tseng C.T., Peters C.J., and Makino S. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 26 6 (2008) 797-808
77. Madani T.A., Al-Mazrou Y.Y., Al-Jeffri M.H., Mishkhas A.A., Al-Rabeah A.M., Turkistani A.M., Al-Sayed M.O., Abodahish A.A., Khan A.S., Ksiazek T.G., and Shobokshi O. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin. Infect. Dis. 37 8 (2003) 1084-1092
78. Mangiafico J.A., Sanchez J.L., Figueiredo L.T., LeDuc J.W., and Peters C.J. Isolation of a newly recognized Bunyamwera serogroup virus from a febrile human in Panama. Am. J. Trop. Med. Hyg. 39 6 (1988) 593-596
79. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., and Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 307 5947 (1984) 178-180
80. Meegan J.M. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies. Trans. R. Soc. Trop. Med. Hyg. 73 6 (1979) 618-623
81. Murata K., Lechmann M., Qiao M., Gunji T., Alter H.J., and Liang T.J. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. U. S. A. 100 11 (2003) 6753-6758
82. Naslund J., Lagerqvist N., Habjan M., Lundkvist A., Evander M., Ahlm C., Weber F., and Bucht G. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 385 2 (2009) 409-415
83. Niklasson B.S., Meadors G.F., and Peters C.J. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta. Pathol. Microbiol. Immunol. Scand. [C] 92 4 (1984) 197-200
84. Niklasson B., Peters C.J., Bengtsson E., and Norrby E. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. Vaccine 3 2 (1985) 123-127
85. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 2 (1991) 193-199
86. Noad R., and Roy P. Virus-like particles as immunogens. Trends Microbiol. 11 9 (2003) 438-444
87. Overby A.K., Popov V., Neve E.P., and Pettersson R.F. Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral packaging and budding. J. Virol. 80 21 (2006) 10428-10435
88. Overby A.K., Pettersson R.F., and Neve E.P. The glycoprotein cytoplasmic tail of Uukuniemi virus (Bunyaviridae) interacts with ribonucleoproteins and is critical for genome packaging. J. Virol. 81 7 (2007) 3198-3205
89. Overby A.K., Popov V.L., Pettersson R.F., and Neve E.P. The cytoplasmic tails of Uukuniemi Virus (Bunyaviridae) G(N) and G(C) glycoproteins are important for intracellular targeting and the budding of virus-like particles. J. Virol. 81 20 (2007) 11381-11391
90. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., and Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retrovir. 16 3 (2000) 273-282
91. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., Pushko P., and Tumpey T.M. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 83 11 (2009) 5726-5734
92. Peters C.J., Reynolds J.A., Slone T.W., Jones D.E., and Stephen E.L. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral. Res. 6 5 (1986) 285-297
93. Peters C.J., Jones D., Trotter R., Donaldson J., White J., Stephen E., and Slone Jr. T.W. Experimental Rift Valley fever in rhesus macaques. Arch. Virol. 99 1-2 (1988) 31-44
94. Pittman P.R., Liu C.T., Cannon T.L., Makuch R.S., Mangiafico J.A., Gibbs P.H., and Peters C.J. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18 1-2 (1999) 181-189
95. Remond M., Da Costa B., Riffault S., Parida S., Breard E., Lebreton F., Zientara S., and Delmas B. Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site. Vaccine 27 1 (2009) 93-98
96. Rovinski B., Haynes J.R., Cao S.X., James O., Sia C., Zolla-Pazner S., Matthews T.J., and Klein M.H. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J. Virol. 66 7 (1992) 4003-4012
97. Roy P. Orbiviruses and their replication. In: Fields B.N. (Ed). Virology (2000), Lippincott-Raven
98. Roy P., and Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin. 4 1 (2008) 5-12
99. Roy P., Boyce M., and Noad R. Prospects for improved bluetongue vaccines. Nat. Rev. Microbiol. 7 2 (2009) 120-128
100. Schirmbeck R., Bohm W., and Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 39 1-2 (1996) 111-119
101. Schmaljohn C., and Hooper J. Bunyaviridae: the viruses and their replication. In: Howley P.M., and Howley P.M. (Eds). Fields Virology. 4th ed 2 (2001), Lippincott Williams & Wilkins, Philadelphia 1581-1602 2 vols
102. Schmaljohn C.S., Parker M.D., Ennis W.H., Dalrymple J.M., Collett M.S., Suzich J.A., and Schmaljohn A.L. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170 1 (1989) 184-192
103. Schmitt A.P., Leser G.P., Waning D.L., and Lamb R.A. Requirements for budding of paramyxovirus simian virus 5 virus-like particles. J. Virol. 76 8 (2002) 3952-3964
104. Shi X., and Elliott R.M. Analysis of glycoproteins of viruses in the family Bunyaviridae. Methods Mol. Biol. 379 (2007) 137-148
105. Shi X., Kohl A., Leonard V.H., Li P., McLees A., and Elliott R.M. Requirement of the N-terminal region of orthobunyavirus nonstructural protein NSm for virus assembly and morphogenesis. J. Virol. 80 16 (2006) 8089-8099
106. Shi X., Kohl A., Li P., and Elliott R.M. Role of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesis. J. Virol. 81 18 (2007) 10151-10160
107. Shi X., Goli J., Clark G., Brauburger K., and Elliott R.M. Functional Analysis of the Bunyamwera Orthobunyavirus Gc Glycoprotein. J. Gen. Virol. (2009)
108. Shoemaker T., Boulianne C., Vincent M.J., Pezzanite L., Al-Qahtani M.M., Al-Mazrou Y., Khan A.S., Rollin P.E., Swanepoel R., Ksiazek T.G., and Nichol S.T. Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg. Infect. Dis. 8 12 (2002) 1415-1420
109. Sitrin R.D., Wampler D.E., and Ellis R.W. Survey of licensed hepatitis B vaccines and their production processes. In: Ellis R.W. (Ed). Hepatitis B vaccines in clinical practice (1993), Marcel Dekker Inc., New York 83-102
110. Soneoka Y., Kingsman S.M., and Kingsman A.J. Mutagenesis analysis of the murine leukemia virus matrix protein: identification of regions important for membrane localization and intracellular transport. J. Virol. 71 7 (1997) 5549-5559
111. Spik K., Shurtleff A., McElroy A.K., Guttieri M.C., Hooper J.W., and SchmalJohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24 21 (2006) 4657-4666
112. Suomalainen M., Hultenby K., and Garoff H. Targeting of Moloney murine leukemia virus gag precursor to the site of virus budding. J. Cell Biol. 135 6 Pt 2 (1996) 1841-1852
113. Suzich J.A., Kakach L.T., and Collett M.S. Expression strategy of a phlebovirus: biogenesis of proteins from the Rift Valley fever virus M segment. J. Virol. 64 4 (1990) 1549-1555
114. Swanepoel R., and Coetzer J.A.W. Rift Valley fever. In: Coetzer J.A.W., and Tustin R.C. (Eds). Infectious diseases of livestock with special reference to South Africa. 2nd edition ed (2003), Oxford University Press Southern Africa, Cape Town
115. Swenson D.L., Warfield K.L., Negley D.L., Schmaljohn A., Aman M.J., and Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23 23 (2005) 3033-3042
116. Swenson D.L., Warfield K.L., Larsen T., Alves D.A., Coberley S.S., and Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert. Rev. Vaccines 7 4 (2008) 417-429
117. Szecsi J., Boson B., Johnsson P., Dupeyrot-Lacas P., Matrosovich M., Klenk H.D., Klatzmann D., Volchkov V., and Cosset F.L. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol. J. 3 (2006) 70
118. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., and Estes M.K. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108 3 (2003) 241-247
119. Thall A.D., Maly P., and Lowe J.B. Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J. Biol. Chem. 270 37 (1995) 21437-21440
120. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., Holden-Wiltse J., Liang H., Gilbert A., and Cox M. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297 14 (2007) 1577-1582
121. USDA. Agricultural Bioterrorism Protection Act of 2002; possession, use, and transfer of biological agents and toxins. In: USDA A. (Ed). Fed Register (2005) 13241-13292 Vol. Part II. 7 CFR Part 331 and 9 CFR Part 121
122. Vialat P., Muller R., Vu T.H., Prehaud C., and Bouloy M. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res. 52 1 (1997) 43-50
123. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M., Kazzaz J., Montomoli E., Del Giudice G., Rappuoli R., and O'Hagan D.T. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 4 (2008) 552-561
124. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., and Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24 49-50 (2006) 7181-7189
125. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., Aman M.J., and Bavari S. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U. S. A. 100 26 (2003) 15889-15894
126. Warfield K.L., Swenson D.L., Negley D.L., Schmaljohn A.L., Aman M.J., and Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 22 25-26 (2004) 3495-3502
127. Warfield K.L., Olinger G., Deal E.M., Swenson D.L., Bailey M., Negley D.L., Hart M.K., and Bavari S. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J. Immunol. 175 2 (2005) 1184-1191
128. Warfield K.L., Swenson D.L., Demmin G., and Bavari S. Filovirus-like particles as vaccines and discovery tools. Expert. Rev. Vaccines 4 3 (2005) 429-440
129. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., and Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196 Suppl 2 (2007) S430-S437
130. Wasmoen T.L., Kakach L.T., and Collett M.S. Rift Valley fever virus M segment: cellular localization of M segment-encoded proteins. Virology 166 1 (1988) 275-280
131. Watanabe S., Watanabe T., Noda T., Takada A., Feldmann H., Jasenosky L.D., and Kawaoka Y. Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J. Virol. 78 2 (2004) 999-1005
132. WHO. Outbreaks of Rift Valley fever in Kenya, Somalia and United Republic of Tanzania, December 2006-April 2007. Wkly. Epidemiol. Rec. 82 20 (2007) 169-178
133. Ye L., Lin J., Sun Y., Bennouna S., Lo M., Wu Q., Bu Z., Pulendran B., Compans R.W., and Yang C. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 351 2 (2006) 260-270
134. Yoshinaka Y., Katoh I., Copeland T.D., and Oroszlan S. Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc. Natl. Acad. Sci. U. S. A. 82 6 (1985) 1618-1622
135. Young K.R., Smith J.M., and Ross T.M. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle. Virology 327 2 (2004) 262-272
136. Young K.R., McBurney S.P., Karkhanis L.U., and Ross T.M. Virus-like particles: designing an effective AIDS vaccine. Methods 40 1 (2006) 98-117
137. Zhou J., Liu W.J., Peng S.W., Sun X.Y., and Frazer I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J. Virol. 73 6 (1999) 4972-4982